Complications of multiple myeloma therapy, part 2: Risk reduction and management of venous thromboembolism, osteonecrosis of the jaw, renal complications, and anemia

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 8, Issue SUPPL. 1, 2010, Pages

  Niesvizky, Ruben ^a   Badros, Ashraf Z ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

Bisphosphonates; Bortezomib; Deep vein thrombosis; Erythropoiesis stimulating agents; Lenalidomide; Pulmonary embolism; Thalidomide

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CHLORHEXIDINE; CREATININE; DELTAPARIN; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; HEMOGLOBIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PAMIDRONIC ACID; PROTEIN C; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE; UNCLASSIFIED DRUG; WARFARIN; ZOLEDRONIC ACID;

ADD ON THERAPY; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ANTICOAGULANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COMPRESSION ULTRASONOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONSERVATIVE TREATMENT; CREATININE CLEARANCE; DIAGNOSTIC TEST; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOGRAPHY; FOOD AND DRUG ADMINISTRATION; GLOMERULUS FILTRATION RATE; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HUMAN; HYPERBARIC OXYGEN; INTERNATIONAL NORMALIZED RATIO; JAW OSTEONECROSIS; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LIFE EXPECTANCY; LONG TERM CARE; LOW DRUG DOSE; LOW LEVEL LASER THERAPY; LUNG ANGIOGRAPHY; LUNG EMBOLISM; MAGNETIC RESONANCE ANGIOGRAPHY; MONOTHERAPY; MORTALITY; MOUTH HYGIENE; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; OZONE THERAPY; PATIENT EDUCATION; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; QUALITY OF LIFE; RADIATION DOSE; RADIATION RESPONSE; RECOMMENDED DRUG DOSE; RISK FACTOR; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

EID: 77649139818     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2010.0112     Document Type: Conference Paper

References (52)

1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(Suppl 6):S381-S453.
2. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809-815.
3. Anderson KC, Alsina M, Bensinger W, et al. NCCN clinical practice guidelines in oncology: multiple myeloma, v 2.2010. Available at www.NCCN.org. Accessed August 12,2009.
4. Brandenburg NA, Goss TF, Knight T, et al. Evaluation of the relationship between venous thromboembolism risk factors and the use of antithrombotic prophylaxis in multiple myeloma patients treated with thalidomide and dexamethasone combination regimens [abstract]. Blood 2008;112:Abstract 2369.
5. Zangari M, Elice F, Fink L, Tricot G. Thrombosis in multiple myeloma. Expert Rev Anticancer Ther 2007;7:307-315.
6. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest 2003;124(Suppl 3):S58-S68.
7. Talamo GP, Ibrahim S, Claxton D, et al. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. Blood Coagul Fibrinolysis 2009;20:337-339.
8. Niesvizky R, Martinez-Banos D, Jalbrzikowski J, et al. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leuk Lymphoma 2007;48:2330-2337.
9. Coleman M, Vigliano EM, Weksler ME, Nachman RL. Inhibition of fibrin monomer polymerization by lambda myeloma globulins. Blood 1972;39:210-223.
10. Spicka I, Rihova Z, Kvasnicka J, et al. Disturbances of anticoagulation and fibrinolytic systems in monoclonal gammopathies - another mechanism of M-protein interference with hemostasis. Thromb Res 2003;112:297-300.
11. Zangari M, Saghafifar F, Mehta P, et al. The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost 2003;29:275-282.
12. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414-423.
13. Rajkumar SV, Rosinol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008;26:2171-2177.
14. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-2142.
15. Gray KN, Chu D, Wu S, Lin RZ. Risk of venous thromboembolism with thalidomide in cancer patients: a systematic review and meta-analysis of randomized controlled trials [abstract]. Blood 2008;112:Abstract 3820.
16. Bennett CL, Angelotta C, Yamold PR, et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 2006;296:2558-2560.
17. Sharma RA, Steward WP, Daines CA, et al. Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. Eur J Cancer 2006;42:2318-2325.
18. Niesvizky R, Jayabalan DS, Christos PJ, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008;111:1101-1109.
19. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-2132.
20. Boen M, McKoy J, West D, et al. Thalidomide (thal), lenalidomide (len), and dexamethasone (dex)-associated venous thromboembolism (VTE) and reported VTE rates pre- and post-FDA approval: optimal prophylaxis strategies are still unclear [abstract]. Blood 2008;112:Abstract 2403.
21. Jacobus S, Kumar S, Callander NS, et al. Effect of venous thrombotic events on overall survival in multiple myeloma: analysis of thrombotic events occurring in E4A03A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma, a trial coordinated by the Eastern Cooperative Oncology Group (ECOG) [abstract]. Blood 2008;112: Abstract 1740.
22. Zangari M, Guerrero J, Cavallo F, et al. Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma. Haematologica 2008;93:953-954.
23. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498.
24. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-917.
25. Heit JA, Silverstein MD, Mohr DN, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999;159:445-453.
26. Bauer KA. The thrombophilias: well-defined risk factors with uncertain therapeutic implications [editorial]. Ann Intern Med 2001;135:367-373.
27. Epogen (epoetin alfa) for injection [package insert]. Thousand Oaks, CA: Amgen, Inc.; 2009.
28. Procrit (epoetin alfa) for injection [package insert]. Raritan, NJ: Ortho Biotech Products, L.P., 2009.
29. Aranesp (darbepoetin alfa) [package insert]. Thousand Oaks, CA: Amgen, Inc.; 2008.
30. Lonial S, Richardson PG, San Miguel J, et al. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol 2008;143:222-229.
31. Bozlar U, Gaughen JR, Nambiar AP, Hagspiel KD. Imaging diagnosis of acute pulmonary embolism. Expert Rev Cardiovasc Ther 2007;5:519-529.
32. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945-952.
33. Migliorati CA, Casiglia J, Epstein J, et al. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 2005;136:1658-1668.
34. Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med 2009;122(2 Suppl):S33-S45.
35. Badros A, Terpos E, Katodritou E, et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol 2008;26:5904-5909.
36. Mehrotra B, Ruggiero S. Bisphosphonate complications including osteonecrosis of the jaw. Hematology Am Soc Hematol Educ Program 2006:356-360, 515.
37. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25:2464-2472.
38. Corso A, Varettoni M, Zappasodi P, et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 2007;21:1545-1548.
39. Desikan R, Veksler Y, Raza S, et al. Nephrotic proteinuria associated with high-dose Pamidronate in multiple myeloma. Br J Haematol 2002;119:496-499.
40. Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64:281-289.
41. Markowitz GS, Perazella MA. Drug-induced renal failure: a focus on tubulointerstitial disease. Clin Chim Acta 2005;351:31-47.
42. Zometa (zoledronic acid) injection [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2008.
43. Dimopoulos MA, Kastritis E, Rosinol L, et al. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008;22:1485-1493.
44. Blade J, Rosinol L. Complications of multiple myeloma. Hematol Oncol Clin North Am 2007;21:1231-1246.
45. Mittelman M. The implications of anemia in multiple myeloma. Clin Lymphoma 2003;4(Suppl 1):S23-S29.
46. Ludwig H, Rai K, Blade J, et al. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations. Hematol J 2002;3:121-130.
47. Birgegard G. Managing anemia in lymphoma and multiple myeloma. Ther Clin Risk Manag 2008;4:527-539.
48. Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001;93:1204-1214.
49. Lyman GH, Glaspy J. Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review. Cancer 2006;106:223-233.
50. Baz R, Walker E, Choueiri TK, et al. Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. Acta Haematol 2007;117:162-167.
51. Katodritou E, Verrou E, Hadjiaggelidou C, et al. Erythropoiesis- stimulating agents are associated with reduced survival in patients with multiple myeloma. Am J Hematol 2008;83:697-701.
52. Rogers GM, Becker PS, Bennett CL, et al. NCCN clinical practice guidelines in oncology: cancer- and chemotherapy-induced anemia, v 1.2009. Available at www.NCCN.org. Accessed August 12,2009.